Shenzhen Yuanzheng Cell Medical Technology

Shenzhen Yuanzheng Cell Medical Technology is a biotechnology company focused on the development of innovative cancer immunotherapies, specifically cell-based treatments. Founded in 2013, the company is best known for its proprietary Multi-Antigen Stimulated Cell Therapy (MASCT) platform, which targets multiple tumor-associated antigens simultaneously to overcome tumor heterogeneity. In 2015, the company established a significant joint venture with Jiangsu Hengrui Pharma, known as Hengrui Yuanzheng (HRYZ), to accelerate the clinical advancement of its TCR-T and MASCT pipelines. The company's lead candidates are currently in Phase 1 and Phase 2 clinical trials for indications including soft tissue sarcoma, liver cancer, and HPV-related malignancies.